Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes

Adoptive transfer of antigen–specific cytotoxic T lymphocytes (CTLs) offers safe and effective therapy for certain viral infections and could prove useful in the eradication of tumor cells. Whether or not the infused T cells persist for extended periods, retaining their ability to expand in response to antigenic stimulation, is not known. We now report long–term detection of gene–marked Epstein–Barr virus (EBV)–specific CTLs in immunocompromised patients at risk for the development of EBV lymphoproliferative disease. Infusions of CTLs not only restored cellular immune responses against EBV, but also established populations of CTL precursors that could respond to in vivo or ex vivo challenge with the virus for as long as 18 months. Our findings support wider use of antigen–specific CTLs in adoptive immunotherapy.

[1]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[2]  S. Rosenberg,et al.  T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.

[3]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[4]  D. Cooper,et al.  Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. , 1991, Blood.

[5]  Ronald G. Crystal,et al.  Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.

[6]  H. Heslop,et al.  Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.

[7]  J. Ihle,et al.  An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. , 1992, Blood.

[8]  R. Ahmed,et al.  Cytotoxic T-cell memory without antigen , 1994, Nature.

[9]  E. Sercarz,et al.  Induction of anti-self-immunity to cure cancer , 1995, Cell.

[10]  Polly Matzinger,et al.  Memories are made of this? , 1994, Nature.

[11]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[12]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[13]  R. Krance,et al.  Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse , 1994 .

[14]  S. Riddell,et al.  Principles for adoptive T cell therapy of human viral diseases. , 1995, Annual review of immunology.

[15]  H. Heslop,et al.  Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. , 1995, Journal of hematotherapy.

[16]  P. Doherty,et al.  CD8+ T-cell memory to viruses. , 1994, Current opinion in immunology.

[17]  R. Krance,et al.  Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.

[18]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[19]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[20]  R. Zinkernagel,et al.  Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen , 1992, The Journal of experimental medicine.

[21]  J. Levy,et al.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. , 1991, Clinical and experimental immunology.

[22]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[23]  G. Lenoir,et al.  Geographical prevalence of two types of Epstein-Barr virus. , 1986, Virology.

[24]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.